DAX24.279 -0,1%Est505.704 -0,1%MSCI World4.343 -0,1%Top 10 Crypto15,87 -0,5%Nas23.852 +0,9%Bitcoin97.777 -0,2%Euro1,1657 +0,1%Öl64,19 -2,4%Gold3.958 -0,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
TKMS thyssenkrupp Marine Systems TKMS00 Rheinmetall 703000 NVIDIA 918422 Beyond Meat A2N7XQ PayPal A14R7U Amazon 906866 Tesla A1CX3T DroneShield A2DMAA Deutsche Telekom 555750 RENK RENK73 Nordex A0D655 Infineon 623100 Lufthansa 823212 AMD (Advanced Micro Devices) 863186 Novo Nordisk A3EU6F
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt etwas leichter -- Wall Street höher -- Nordex erhöht Gewinnprognose -- Deutsche Börse, Corning, PayPal, DroneShield, AMD, Telekom, NVIDIA, Symrise, Siltronic, HSBC, TKMS im Fokus
Top News
Gold, Heizöl, Silber & Co. am Dienstagabend Gold, Heizöl, Silber & Co. am Dienstagabend
Online Broker Vergleich - die besten Aktiendepots und Trading-Plattformen im Test Online Broker Vergleich - die besten Aktiendepots und Trading-Plattformen im Test
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
ZERO WINTERDEAL 2025: Bis zu 300 € Prämie + Gratis-Aktie + finanzen.net MSCI World-ETF – Jetzt informieren!

Eli Lilly Aktie

Kaufen
Verkaufen
Eli Lilly Aktien-Sparplan
702,50 EUR -3,80 EUR -0,54 %
STU
820,73 USD -5,36 USD -0,65 %
BTT
Eli Lilly jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.670,81 Mrd. EUR

KGV65,91Div. Rendite0,67%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN858560

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS5324571083

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolLLY

Eli Lilly Aktien News

DatumMeistgelesen
EN, Eli LillyLilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients
PR NewswireLilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients
EN, Eli LillyLilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impact
Wer­bungEli Lilly-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireLilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impact
EN, Eli LillyLilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis
PR NewswireLilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis
EN, Eli LillyLilly declares fourth-quarter 2025 dividend
PR NewswireLilly declares fourth-quarter 2025 dividend
EN, Eli LillyLilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea
PR NewswireLilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea
PR NewswireLilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis
EN, Eli LillyLilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis
PR NewswireLilly to Acquire Adverum Biotechnologies
EN, Eli LillyLilly to Acquire Adverum Biotechnologies
PR NewswireLilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
PR NewswireLilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis
EN, Eli LillyLilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis
EN, Eli LillyLilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
PR NewswireLilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
EN, Eli LillyLilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
PR NewswireLilly confirms date and conference call for third-quarter 2025 financial results announcement
EN, Eli LillyLilly confirms date and conference call for third-quarter 2025 financial results announcement
PR NewswireLilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
EN, Eli LillyLilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
PR NewswireLilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
EN, Eli LillyLilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
EN, Eli LillyWHO Foundation and Lilly Collaborate to Support Global Dementia Action Plan
PR NewswireLilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
EN, Eli LillyLilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis

Eli Lilly News

Eli Lilly News: auf dieser Seite finden Sie alle Eli Lilly News und Nachrichten zur Eli Lilly Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Eli Lilly News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Eli Lilly News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.